Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2024-08-02 Earnings Release
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for JW Life Science, detailing key financial metrics like revenue, operating profit, and net income for the second quarter of 2024. It provides a summary of financial performance rather than a full report, fitting the definition of an Earnings Release (ER). Q2 2024
2024-08-02 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for JW Life Science, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial information, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for JW Life Science for the first quarter of 2024. It provides key financial highlights such as revenue, operating profit, and net income in a summary table format. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results. Q1 2024
2024-05-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders (JW Holdings and related parties) in JW Life Science. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-04-03 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a '최대주주등소유주식변동신고서' (Report on Changes in Shareholding by Major Shareholders and Related Parties). It details specific transactions (disposals due to retirement) by company executives (Lee Hyun-soon and Cha Sung-nam). This falls under the category of Director's Dealing (DIRS) as it reports personal share transactions by company directors and executives.
2024-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and director appointments. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.